N-Acetyl Selank is a chemically tweaked version of Selank, a synthetic peptide developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. The change is small on paper: an acetyl group is added to the N-terminus of the peptide. The honest headline is that the modified form has almost no published research attached to it, so most of what gets said about it is borrowed from the parent compound and from chemical reasoning, not from studies on the acetylated molecule itself.
Start with what the derivative actually is. PubChem lists N-Acetyl selank as CID 133082488, molecular formula C35H59N11O10. It is the acetylated relative of Selank, whose own sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Beyond the catalog entry, there is no body of peer-reviewed pharmacology specific to N-Acetyl Selank. No clinical trials, no animal studies under that exact name that we could find. Vendor pages describe it as a research chemical and frame N-terminal acetylation as a way to slow enzymatic breakdown, but that is a chemical rationale, not a demonstrated result for this molecule.
What is documented is mostly about Selank, the parent
Selank was built by extending tuftsin, a naturally occurring immune-signaling peptide, with extra residues to make it more stable. According to the Selank overview on Wikipedia, it acts as a synthetic analogue of human tuftsin and has been studied as an anxiolytic and nootropic.
The mechanism work on Selank is mostly preclinical and from Russian groups:
- BDNF. Intranasal Selank raised brain-derived neurotrophic factor expression in the rat hippocampus in one study, with effects on BDNF mRNA and protein at set time points.
- GABA system. Selank altered the expression of genes tied to GABAergic neurotransmission in cell-culture work, reported in a 2016 paper indexed on PubMed/PMC, without appearing to bind GABA receptors directly.
- Serotonin and enkephalins. Selank has been described as influencing serotonin metabolism and slowing the breakdown of enkephalins and related regulatory peptides.
There is also limited human data on Selank itself. A Russian trial compared Selank against the benzodiazepine medazepam in patients with generalized anxiety disorder and neurasthenia, reporting comparable anxiolytic effect in roughly 60 patients, summarized in this report. The sample is small, the work is largely single-region, and it has not been replicated in independent Western trials. Treat it as preliminary.
The gap matters. Even if you accept the Selank literature at face value, none of it was run on the acetylated derivative. Adding an acetyl group can change how a peptide is absorbed, how long it lasts, and what it does. So findings on Selank cannot simply be transferred to N-Acetyl Selank.
Regulatory and quality notes
Selank is sold by prescription in Russia and is not approved by the FDA or EMA. N-Acetyl Selank has no approval anywhere we can document and is offered strictly as a research chemical, not for human consumption. None of this is medical or dosing advice.
For anyone evaluating sellers, the testing angle is where attention belongs, because the science won't settle it. With an obscure derivative like this, the real questions are identity and purity: is the vial actually the acetylated peptide rather than plain Selank or something else, and what does an independent certificate of analysis show? Ask for third-party HPLC and mass-spec data tied to the specific batch, check that the reported mass lines up with the C35H59N11O10 formula, and weigh that against the independent vendor ratings this site aggregates rather than relying on a product description.
Bottom line: the parent peptide has a modest, mostly preclinical and mostly Russian evidence base, and the acetylated version riding on its name has effectively none of its own.